



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- Ex Cont*
- R¹ is
- 1) -CN,
 - 2) -NO₂,
 - 3) a halogen, or
 - 4) (C₁-C₄)-alkyl-C(O)-OH;
- R² is
- 1) -CF₃,
 - 2) a halogen, or
 - 3) -CN;
- R³ is
- 1) =O,
 - 2) =S, or
 - 3) =NH;
- X is
- 1) a radical of formula II




or

- 2) a radical of formula III



or X and Y together form a group of formula IV




in which R⁴ is

- 1) hydrogen atom,
- 2) (C₁-C₆)-alkyl-,
- 3) (C₂-C₆)-alkenyl-, or
- 4) (C₁-C₆)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C₁-C₄)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

Y is 1) a radical of formula V



in which:

R⁵ is, independently of R⁶, a hydrogen atom or (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R⁶ is, independently of R⁵, (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
- b) phenyl-(CH₂)_m-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

B+ Contd


~~-COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,~~

~~c) -COOH,~~

~~d) -CN, or~~

~~e) -CF₃, or~~


~~2) a radical of formula VI,~~



~~in which R⁴ is as defined above; and~~

~~Z is 1) -O- or~~

~~2) a radical of formula VII~~



~~wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.~~

B2 Sub C


22. (Amended) A process for making a product for treatment of androgenic alopecia, comprising the step of forming said product by bringing together:

- at least one physiologically tolerated film-forming agent;
- at least one physiologically tolerated solvent;
- at least one plasticizer; and

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP


1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- B² cont*
- | | | |
|-------------------|----|--|
| R ¹ is | 1) | -CN, |
| | 2) | -NO ₂ , |
| | 3) | a halogen, or |
| | 4) | (C ₁ -C ₄)-alkyl-C(O)-OH; |
| R ² is | 1) | -CF ₃ , |
| | 2) | a halogen, or |
| | 3) | -CN; |
| R ³ is | 1) | =O, |
| | 2) | =S, or |
| | 3) | =NH; |
| X is | 1) | a radical of formula II |




or


- 2) a radical of formula III

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



or X and Y together form a group of formula IV




in which R⁴ is

- 1) hydrogen atom,
- 2) (C₁-C₆)-alkyl-,
- 3) (C₂-C₆)-alkenyl-, or
- 4) (C₁-C₆)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C₁-C₄)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

Y is 1) a radical of formula V



in which:

R⁵ is, independently of R⁶, a hydrogen atom or (C₁-C₄)-alkyl,


wherein the alkyl is unsubstituted or mono- to tetrasubstituted by

halogens, and R⁶ is, independently of R⁵, (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

B²
cont


- B²
cont
- a) halogens,
 - b) phenyl-(CH₂)_m-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
 - c) -COOH,
 - d) -CN, or
 - e) -CF₃, or

- 2) a radical of formula VI,



in which R⁴ is as defined above; and

- Z is
- 1) -O- or
 - 2) a radical of formula VII




wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

23. (Amended) A process for making a product intended for treatment of seborrhea or acne, comprising the step of forming said product by bringing together:


- a) at least one physiologically tolerated film-forming agent;

- b) at least one physiologically tolerated solvent;
c) at least one plasticizer; and
d) a compound of the formula I




or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- | | | |
|-------------------|----|--|
| R ¹ is | 1) | -CN, |
| | 2) | -NO ₂ , |
| | 3) | a halogen, or |
| | 4) | (C ₁ -C ₄)-alkyl-C(O)-OH; |
| R ² is | 1) | -CF ₃ , |
| | 2) | a halogen, or |
| | 3) | -CN; |
| R ³ is | 1) | =O, |
| | 2) | =S, or |
| | 3) | =NH; |
| X is | 1) | a radical of formula II |




or

2) a radical of formula III



or X and Y together form a group of formula IV




in which R⁴ is

- 1) hydrogen atom,
- 2) (C₁-C₆)-alkyl-,
- 3) (C₂-C₆)-alkenyl-, or
- 4) (C₁-C₆)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C₁-C₄)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

Y is 1) a radical of formula V



in which:

R⁵ is, independently of R⁶, a hydrogen atom or (C₁-C₄)-alkyl,

wherein the alkyl is unsubstituted or mono- to tetrasubstituted by


B²
cont

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com


halogens, and R^6 is, independently of R^5 , (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- B²
Contd
- a) halogens,
 - b) phenyl- $(CH_2)_m$ -, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
 - c) -COOH,
 - d) -CN, or
 - e) -CF₃, or
- 2) a radical of formula VI,



in which R^4 is as defined above; and

- Z is
- 1) -O- or
 - 2) a radical of formula VII




wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

B3
Sub C1

28. (Amended) A process for treatment of seborrhea or acne, comprising the step of applying to a patient in need or desire thereof a composition comprising:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I




or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:


- | | |
|----------|---|
| R^1 is | 1) -CN, |
| | 2) -NO ₂ , |
| | 3) a halogen, or |
| | 4) (C ₁ -C ₄)-alkyl-C(O)-OH; |
| R^2 is | 1) -CF ₃ , |
| | 2) a halogen, or |
| | 3) -CN; |
| R^3 is | 1) =O, |
| | 2) =S, or |
| | 3) =NH; |
| X is | 1) a radical of formula II |

or

2) a radical of formula III



or X and Y together form a group of formula IV




in which R⁴ is

- 1) hydrogen atom,
- 2) (C₁-C₆)-alkyl-,
- 3) (C₂-C₆)-alkenyl-, or
- 4) (C₁-C₆)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C₁-C₄)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

Y is 1) a radical of formula V




B3
Cont

in which:

*B3
cont*


R^5 is, independently of R^6 , a hydrogen atom or (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5 , (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
 - b) phenyl- $(CH_2)_m$ -, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
 - c) -COOH,
 - d) -CN, or
 - e) -CF₃, or
- 2) a radical of formula VI,



in which R^4 is as defined above; and

- Z is
- 1) -O- or
 - 2) a radical of formula VII




FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

29. (Amended) A cosmetic composition comprising:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R¹ is
- 1) -CN,
 - 2) -NO₂,
 - 3) a halogen, or
 - 4) (C₁-C₄)-alkyl-C(O)-OH;


- R² is
- 1) -CF₃,
 - 2) a halogen, or
 - 3) -CN;

- R³ is
- 1) =O,
 - 2) =S, or

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP


1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

- X is
- 3) =NH;
 - 1) a radical of formula II




or

- 2) a radical of formula III



or X and Y together form a group of formula IV




- in which R^4 is
- 1) hydrogen atom,
 - 2) (C₁-C₆)-alkyl-,
 - 3) (C₂-C₆)-alkenyl-, or
 - 4) (C₁-C₆)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C₁-C₄)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

- Y is 1) a radical of formula V




B³
Cont

in which:

R^5 is, independently of R^6 , a hydrogen atom or (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5 , (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- B3
Cont
- a) halogens,
 - b) phenyl- $(CH_2)_m$ -, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
 - c) -COOH,
 - d) -CN, or
 - e) -CF₃, or
- 2) a radical of formula VI,



in which R^4 is as defined above; and

- Z is
- 1) -O- or
 - 2) a radical of formula VII

